BCAM
NVO

Boston Common Asset Management’s Novo Nordisk NVO Stock Holding History

Boston Common Asset Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-61,958
Closed -$3.15M – 194
2025
Q4 		$3.15M Sell
61,958
-4,526
-7% -$231K 0.19% 114
2025
Q3 		$3.69M Sell
66,484
-17,268
-21% -$1.01M 0.1% 214
2025
Q2 		$5.78M Sell
83,752
-2,435
-3% -$166K 0.16% 176
2025
Q1 		$5.98M Buy
86,187
+32,927
+62% +$2.72M 0.18% 165
2024
Q4 		$4.58M Buy
53,260
+2,967
+6% +$321K 0.13% 184
2024
Q3 		$5.99M Buy
50,293
+4,119
+9% +$549K 0.16% 172
2024
Q2 		$6.59M Sell
46,174
-3,832
-8% -$508K 0.17% 164
2024
Q1 		$6.42M Sell
50,006
-142
-0.3% -$16.9K 0.15% 173
2023
Q4 		$5.19M Sell
50,148
-4,383
-8% -$433K 0.12% 196
2023
Q3 		$4.96M Sell
54,531
-58,073
-52% -$5.12M 0.12% 196
2023
Q2 		$9.11M Sell
112,604
-32,494
-22% -$2.65M 0.19% 151
2023
Q1 		$11.5M Buy
145,098
+4,728
+3% +$335K 0.24% 141
2022
Q4 		$9.5M Sell
140,370
-7,000
-5% -$410K 0.45% 76
2022
Q3 		$7.34M Sell
147,370
-1,676
-1% -$89.8K 0.38% 87
2022
Q2 		$8.3M Sell
149,046
-19,684
-12% -$1.09M 0.41% 78
2022
Q1 		$9.37M Sell
168,730
-51,972
-24% -$2.67M 0.4% 84
2021
Q4 		$12.4M Sell
220,702
-6,798
-3% -$368K 0.5% 67
2021
Q3 		$10.9M Buy
227,500
+7,418
+3% +$359K 0.47% 73
2021
Q2 		$9.22M Buy
220,082
+12,470
+6% +$483K 0.4% 78
2021
Q1 		$7M Sell
207,612
-2,282
-1% -$81.3K 0.44% 69
2020
Q4 		$7.33M Sell
209,894
-53,098
-20% -$1.84M 0.51% 65
2020
Q3 		$9.13M Buy
262,992
+9,222
+4% +$307K 0.87% 35
2020
Q2 		$8.31M Sell
253,770
-15,074
-6% -$481K 0.89% 40
2020
Q1 		$8.09M Buy
268,844
+12
+0% +$357 1.14% 21
2019
Q4 		$7.78M Sell
268,832
-9,832
-4% -$272K 0.91% 37
2019
Q3 		$7.2M Sell
278,664
-2,816
-1% -$71.2K 0.89% 39
2019
Q2 		$7.18M Sell
281,480
-64,860
-19% -$1.6M 0.89% 37
2019
Q1 		$9.06M Buy
346,340
+33,680
+11% +$828K 1.18% 21
2018
Q4 		$7.2M Buy
312,660
+3,296
+1% +$73.2K 1.05% 27
2018
Q3 		$7.29M Buy
309,364
+9,778
+3% +$239K 0.9% 35
2018
Q2 		$6.91M Buy
299,586
+2,782
+0.9% +$66.1K 0.86% 46
2018
Q1 		$7.31M Buy
296,804
+5,482
+2% +$144K 0.86% 42
2017
Q4 		$7.82M Buy
291,322
+4,824
+2% +$123K 0.93% 36
2017
Q3 		$6.9M Buy
286,498
+4,008
+1% +$90.6K 0.86% 36
2017
Q2 		$6.06M Buy
282,490
+217,950
+338% +$4.4M 0.8% 42
2017
Q1 		$1.11M Buy
+64,540
New +$1.12M 0.15% 110
2014
Q3 		– Sell
-5,750
Closed -$133K – 297
2014
Q2 		$133K Sell
5,750
-18,290
-76% -$404K 0.01% 261
2014
Q1 		$549K Sell
24,040
-79,650
-77% -$1.7M 0.03% 231
2013
Q4 		$1.92M Sell
103,690
-20,180
-16% -$352K 0.11% 173
2013
Q3 		$2.1M Sell
123,870
-5,020
-4% -$84.4K 0.12% 162
2013
Q2 		$2M Buy
+128,890
New +$2.15M 0.12% 162

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $147M AUM 25.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return

Boston Common Asset Management's NVO Position: Q1 2026 in Review

Boston Common Asset Management sold out of Novo Nordisk (NVO) in Q1 2026, closing a stake of 61,958 shares — an estimated $3.15M sold.

Boston Common Asset Management first reported a position in NVO in Q2 2013 and held it in 41 quarters. The position peaked at $12.4M in Q4 2021. 1,277 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • Boston Common Asset Management reported no remaining Novo Nordisk position as of Q1 2026 after selling out during the quarter.
  • Boston Common Asset Management sold 61,958 Novo Nordisk shares in Q1 2026, an estimated $3.15M.
  • Boston Common Asset Management first reported a position in Novo Nordisk in Q2 2013 and held it in 41 quarters.
  • Boston Common Asset Management's Novo Nordisk position peaked at $12.4M in Q4 2021.
  • 1,277 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on Boston Common Asset Management's 13F filing for Q1 2026, filed 7 May 2026.